FSC
NBIX icon

Full Sail Capital’s Neurocrine Biosciences NBIX Stock Holding History

Full Sail Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$361K Buy
+2,572
New +$348K 0.02% 197

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Full Sail Capital's NBIX Position: Q3 2025 in Review

Full Sail Capital opened a new position in Neurocrine Biosciences (NBIX) in Q3 2025: 2,572 shares worth $361K. The stake represents 0.02% of the portfolio and ranks #197 among its holdings.

649 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • Full Sail Capital held 2,572 shares of Neurocrine Biosciences worth $361K as of Q3 2025.
  • Neurocrine Biosciences was a new Full Sail Capital position in Q3 2025.
  • Neurocrine Biosciences made up 0.02% of Full Sail Capital's portfolio in Q3 2025, its #197 holding.
  • 649 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Full Sail Capital's 13F filing for Q3 2025, filed 14 Nov 2025.